Maynard Um
-
-
-
-
-
-
-
Evaxion completes phase 2 cancer vaccine trial extension
-
-
-
-
-
-
-
Sidoti Events, LLC's Year-End Virtual Investor Conference
-
-
-
-
-
-
-
Evaxion Biotech (EVAX) Tops Q3 EPS by 1c
-
-
-
-
-
-
-
Evaxion out-licenses EVX-B3 vaccine to MSD for $7.5 million upfront
-
-
-
-
-
-
-
Evaxion Biotech (EVAX) presents EVX-01 data
-
-
-
-
-
-
-
Evaxion Biotech (EVAX) establishes new AI-derived precision cancer vaccine concept
-
-
-
-
-
-
-
Evaxion Biotech (EVAX) expands vaccine development collaboration with MSD
-
445,673 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

